Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The pharmaceutical warehousing market size is forecasted to increase by $15,752M from 2022 to 2027, at a CAGR of 4.9%, according to a study by Technavio. The growth of the market will be driven by the rise in demand for outsourcing pharmaceutical warehousing services, increased focus on quality and product sensitivity in the pharma industry, and ...
read more
Marchesini Group announced it acquired Rejves Machinery Srl, a company from Marmirolo (Mantua) that produces filling and capping machines for pharmaceutical, chemical, cosmetic and food products.
read more
NJM, a ProMach product brand, and Steelco, a member of the Miele Group, announce that NJM has been appointed exclusive North American representative of pharma and biopharma equipment for Steelco.
read more
The pharmaceutical gelatin market is projected to reach $1.5B by 2027 from $1.1B in 2022, at a CAGR of 5.5% during the forecast period according to a new report by MarketsandMarkets™.
read more
JRS Pharma announced the construction of a new manufacturing facility in Cedar Rapids, Iowa. Starting in the fall of 2022, with operations commencing in early 2024, the expansion will add capacity to manufacture microcrystalline cellulose products.
read more
Vantage Nutrition, an ACG Group company, announced that it has acquired Philadelphia-based AquaCap
read more
The Asia Pacific infant, child, and maternal probiotic supplements market is expected to grow from $201.82M in 2022 to $346.65M by 2028; it is estimated to grow at a CAGR of 9.4% from 2022 to 2028, according to a report from Research & Markets.
read more
The global antacids market will reach $10.50B in 2027, at a CAGR of 3.78%, according to a study by Reportlinker. Poor lifestyle adoptions such as deskbound jobs, poor sleep quality, and irregular dietary habits, which increases the acidity level of the stomach and lead to gastroesophageal reflux disease, are essential drivers for the evolution of ...
read more
Rigel Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REZLIDHIA™ (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
read more
The global vegan supplement market, valued at $9.27B is projected to reach $22.11B by 2030, growing at a CAGR of 10.35% during the forecast period, according to a report from Polaris Market Research.
read more
Aurinia Pharmaceuticals announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin.
read more
Approximately 80 approved antiviral drugs only target 10 of the 220 known viruses that are responsible for causing multiple life-threatening infectious diseases in humans. That gap–combined with an increasing awareness of a need to fill it, triggered by COVID-19–is fueling more collaborative research, according to a report by Research & Markets.
read more
WuXi STA, a subsidiary of WuXi AppTec and a global Contract Research, Development and Manufacturing Organization (CRDMO) based in Wuxi City, China, announced the partnership with Multiply Labs (based in San Francisco, CA, USA), a robotics company that has developed automated manufacturing systems to produce individualized drugs.
read more
The global iodine deficiency drug industry was pegged at $3.7B in 2021, and is expected to reach $6.5B by 2031, growing at a CAGR of 5.8% from 2022 to 2031, according to a report from Allied Market Research.
read more
Kaneka Corporation, Tokyo, will manufacture and supply intermediates to Shionogi & Co., in Osaka, for use in Xocova®*1 (Ensitrelvir Fumaric Acid) Tablets 125mg), a drug for the treatment of SARS-Cov-2 infection.
read more